Business Description
Jupiter Neurosciences Inc
NAICS : 325412
SIC : 2834
ISIN : US48208B2034
Total Employee Number:
5Description
Jupiter Neurosciences Inc is a clinical-stage research and development company focused on developing treatments for neuroinflammation through the resveratrol platform. Its platform product, JOTROL, is an enhanced oral formulation of resveratrol, which has many potential indications. In the larger disease areas, which are targeting Parkinson's Disease. The group is presently in the process of conducting a Phase IIa clinical trial in Parkinson's Disease. The company operates through two reportable segments: premium nutritional supplements and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. It generates the majority of its revenue from Premium Nutritional Supplements, which includes commercialization and sales of the Company's Nugevia product line.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.49 | |||||
Equity-to-Asset | -0.71 | |||||
Debt-to-Equity | -1.74 | |||||
Debt-to-EBITDA | -0.54 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -21.02 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -47.7 | |||||
3-Year EBITDA Growth Rate | -24.7 | |||||
3-Year EPS without NRI Growth Rate | -25.3 | |||||
3-Year FCF Growth Rate | -60.1 | |||||
3-Year Book Growth Rate | 37.5 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 9.49 | |||||
9-Day RSI | 17.1 | |||||
14-Day RSI | 24.3 | |||||
3-1 Month Momentum % | -22.78 | |||||
6-1 Month Momentum % | -66.06 | |||||
12-1 Month Momentum % | -82.72 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.51 | |||||
Quick Ratio | 0.48 | |||||
Cash Ratio | 0.35 | |||||
Days Inventory | 11242 | |||||
Days Sales Outstanding | 26.71 | |||||
Days Payable | 17709.8 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.6 | |||||
Shareholder Yield % | -23.11 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 87.81 | |||||
Operating Margin % | -22765.85 | |||||
Net Margin % | -22385.37 | |||||
EBITDA Margin % | -21939.02 | |||||
FCF Margin % | -14102.44 | |||||
OCF Margin % | -14102.44 | |||||
ROA % | -218.32 | |||||
ROIC % | -199.53 | |||||
3-Year ROIIC % | -902.31 | |||||
ROC (Joel Greenblatt) % | -25700 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 1.89 | |||||
PS Ratio | 56.76 | |||||
EV-to-EBIT | -0.88 | |||||
EV-to-EBITDA | -0.88 | |||||
EV-to-Revenue | 193.8 | |||||
EV-to-Forward-Revenue | 1.15 | |||||
EV-to-FCF | -1.37 | |||||
Earnings Yield (Greenblatt) % | -113.64 | |||||
FCF Yield % | -105.59 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:JUNS
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Jupiter Neurosciences Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.041 | ||
| EPS (TTM) ($) | -0.27 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 81.4 | ||
| 14-Day RSI | 24.3 | ||
| 14-Day ATR ($) | 0.029998 | ||
| 20-Day SMA ($) | 0.18298 | ||
| 12-1 Month Momentum % | -82.72 | ||
| 52-Week Range ($) | 0.107 - 1.8395 | ||
| Shares Outstanding (Mil) | 48.22 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Jupiter Neurosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Jupiter Neurosciences Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 108 days | ||
| Second quarter earnings results for 2026 | 2026-08-19 | In 22 days | ||
| General meeting for 2026 | 2026-07-22 10:00 | 0.17 (-25.50%) | ||
| First quarter earnings results for 2026 | 2026-05-14 | 0.34 (-6.40%) | ||
| Annual report for 2025 | 2026-04-01 | 0.38 (+11.30%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 1.31 (-2.24%) | ||
| Second quarter earnings results for 2025 | 2025-08-19 | 1.24 (-1.59%) |
Show
Entries
Jupiter Neurosciences Inc Frequently Asked Questions
What is Jupiter Neurosciences Inc(JUNS)'s stock price today?
The current price of JUNS is $0.11. The 52 week high of JUNS is $1.84 and 52 week low is $0.11.
When is next earnings date of Jupiter Neurosciences Inc(JUNS)?
The next earnings date of Jupiter Neurosciences Inc(JUNS) is 2026-08-19 Est..
Does Jupiter Neurosciences Inc(JUNS) pay dividends? If so, how much?
Jupiter Neurosciences Inc(JUNS) does not pay dividend.
Guru Commentaries on NAS:JUNS
No articles.
Press Release
Articles on Jupiter Neurosciences Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers